Loading article…
Cannabis-derived treatment eases agitation in 90% of dementia patients, with a THC-CBD combo showing promise in a small phase 2 trial, sparking hope for a new
A THC-CBD oil eased agitation in hospice-eligible dementia patients, with close to 90% improving after 12 weeks in a small phase 2 trial [1]. The study's findings have significant implications for the treatment of dementia, a condition that affects about 6.7 million Americans age 65 and older, a figure projected to reach 13.8 million by 2060 [1].
| At a glance | |
|---|---|
| Improvement rate | 90% |
| Trial duration | 12 weeks |
| Patient population | Hospice-eligible dementia patients |
| Formulation | THC-CBD oil suspension |
The LiBBY trial, short for Life’s end Benefits of cannaBidiol and tetrahYdrocannabinol, was presented at the Alzheimer’s Association International Conference in London [1]. The multicenter, randomized, double-blind, placebo-controlled study enrolled 120 participants with Alzheimer’s disease or another dementia, and the average age was 80 [1]. The study's primary outcome was assessed after two weeks, with follow-up at 12 weeks, and the results showed that the THC-CBD oil suspension eased agitation in hospice-eligible patients with advanced dementia [1].
The study's findings build on earlier work suggesting cannabinoids may help calm some people with dementia [1]. However, other studies have found that using medical or recreational marijuana to ease symptoms of numerous mental health conditions doesn't work [3]. The Alzheimer’s Association says there is very little scientific evidence on cannabis and cannabis-derived products in Alzheimer’s disease or other dementias, and that cannabis is not approved by the Food and Drug Administration for dementia treatment [1]. Researchers at the University of Kentucky are part of a groundbreaking clinical trial exploring the use of medical marijuana in managing symptoms of late-stage dementia [2].
The real significance of the study's findings lies in their potential to provide a new avenue of relief for patients and caregivers affected by dementia, a condition that currently has limited treatment options [2]. As researchers continue to explore the potential of cannabis-derived treatments, the question remains whether these findings will translate into meaningful improvements in patient outcomes and quality of life [1].
Coverage is mostly measured — 6 of 6 reports stay neutral.
Every Monday — the token unlocks, Fed dates & catalysts set to move crypto and markets this week. So you’re never blindsided.
Free · 3-min read · one-click unsubscribe
AI-assisted synthesis by the TrendWatcher Editorial Desk · sourced from 3 outlets · Jul 14, 2026 · How we report
A high proportion of put options—over 70% of recent volume—suggests traders are bearish or hedging against a potential decline in Bitcoin price.
Ether options on Derive are predominantly calls, with about 40% of open interest in $2,900‑$3,200 strikes, indicating bullish expectations.
The July 11 expiry puts at $85,000, $100,000 and $106,000 account for roughly 20% of Derive's total Bitcoin options open interest.
Traders cite the upcoming ETHCC conference in Cannes as a catalyst that could drive upward momentum for Ether.
Derive shows a bearish tilt for Bitcoin with heavy put usage, while Deribit has seen traders reduce put positions and increase call buying as Bitcoin prices rose.